Recent Progress in the Pharmacotherapy of Alzheimer’s Disease

Abstract

Alzheimer's disease is the most common major neurocognitive disorder with substantial social and economic impacts. This article is an update on current pharmacotherapy, advancements in biomarker use, and drugs in the pipeline for this disease. To date, no new drug has qualified to be added to the current therapeutic arsenal comprising cholinesterase inhibitors and the NMDA receptor antagonist memantine. Drugs in the pipeline include symptomatic therapies that are neurotransmitter-based, but mostly disease-modifying therapies. The latter have yielded disappointing results by focusing mainly on the two pathophysiological hallmarks of Alzheimer's disease: Aβ amyloid deposits and tau protein aggregates forming neurofibrillary tangles. These unsuccessful trials may have resulted from studying these drugs 'too late' relative to Alzheimer's disease onset, in addition to focusing only on the amyloid cascade. In fact, Alzheimer's disease is a complex multifactorial disease. Combining different biomarkers might enhance our ability to identify those patients most at risk of developing the disease, and better predict their conversion rates. Furthermore, adopting an integrative treatment approach by targeting additional pathophysiological pathways in Alzheimer's disease such as inflammation and oxidative stress could be the key to better outcomes in Alzheimer's disease pharmacotherapy research.

Targeted Metabolic Profiling of Urine Highlights a Potential Biomarker Panel for the Diagnosis of Alzheimer’s Disease and Mild Cognitive Impairment: A Pilot Study

“…AD is the 6th leading cause of death in the United States and it is believed to cost~$290 billion per year in health care [4]. The etiopathogenesis of AD is thought to begin decades before symptoms become apparent, and once symptoms such as memory loss, language problems, and other cognitive problems arise it is too late to treat the disease as the damage has already occurred [5]. The identification of early diagnostic biomarkers capable of identifying those people with AD years before irreversible brain damage has occurred is the number one priority for most grant-awarding institutions.…”

K284-6111 Alleviates Memory Impairment and Neuroinflammation in Tg2576 Mice by Inhibition of Chitinase-3-like 1 Regulating ERK Dependent PTX3 Pathway

“…Alzheimer's disease (AD) is the most common neurodegenerative disease, with 46.8 million people currently suffering from AD worldwide, and the number is expected to reach 131.5 million by 2050 [1]. AD is generally characterized by reduced cognitive function, including memory loss, but it is also characterized by behavioral or psychological symptoms such as anxiety, depression and delusions [2].…”

Open to All: Dementia, Creativity, and Open Ecosystem Innovation

“…At the moment, there is no cure for dementia. Pharmacological interventions aim to improve cognitive functioning or to reduce distressing symptoms, but there is currently no treatment that can convincingly alter the course of the underlying condition (in relation to Alzheimer's for example: Anand et al, 2014;Khoury et al, 2017). With dementia progression, sustaining contact and communication (both verbal and non-verbal) becomes ever-more important in maintaining quality of life and wellbeing.…”